Mr. B Returns to the Activities He Loves
In 2013, Mr. B was referred for a colonoscopy and was ultimately diagnosed with colon cancer. He underwent surgery to remove the tumor and received standard chemotherapy, completing this in May 2014.
In October 2014, Mr. B developed significant rib pain which was found to be due to cancer that had spread. The oncologist performed molecular testing on tissue from his rib, and the analysis revealed a CCDC6-RET fusion. At that time, the patient was treated with standard chemotherapy for advanced colon cancer.
After failing this therapy, Mr. B enrolled on the RXDX-105-01 study. After just 4 weeks of treatment with RXDX-105, a multikinase inhibitor with potent activity against RET, his CEA (cancer biomarker) level decreased significantly. Mr. B said that he felt great; much better than he had in some time.
At the first tumor assessment scan, after 8 weeks on treatment with RXDX-105, the radiologist found it difficult to measure the tumors. Mr. B’s CEA level had decreased by 50% and he continued on study treatment.
At the next tumor assessment scan, after just 16 weeks on treatment, no tumors were observed; Mr. B had experienced a complete response to RXDX-105 treatment. In addition, Mr. B’s CEA level was within normal limits, the lowest level since he was first diagnosed with cancer.
Mr. B’s quality of life improved significantly and he was able to return to the activities he loves, including traveling, carpentry, and helping his daughter build furniture for her house.